{'fraction_non_alphanumeric': 0.02564102564102564, 'fraction_numerical': 0.045364891518737675, 'mean_word_length': 5.383647798742138, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The emergence of acquired HIV-1 drug resistance has nearly stopped in Switzerland.

Alexandra Scherrer from University Hospital Zürich and colleagues recently published an article in Clinical Infectious Diseases (2016; 62 : 1310–317) on the near disappearance of acquired drug resistance in Switzerland. Their study followed 11 094 antiretroviral therapy (ART)-experienced patients from 1999 to 2013. During that period, the emergence of new drug resistance mutations declined from 401 in 1999 to 23 in 2013, and at the end of the study nearly 95% of patients who had initiated ART before 1999 still had good remaining treatment options. Coauthor Huldrych Günthard, also of University Hospital Zürich, says that these findings show that ‘it is possible on the population level to halt the emergence of drug resistance in HIV-treated patients under the best possible circumstances: unrestricted access to healthcare, availability of all drugs for all people, systematic monitoring, and baseline resistance testing’.